| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| KRYSKrystal Biotech, Inc. | 8.18B | 282.01 | 94.00 | 473.02% | 53.3% | 17.48% | 1.46% | 0.01 |
| BMRNBioMarin Pharmaceutical Inc. | 10.58B | 55.07 | 24.92 | 17.97% | 16.82% | 8.59% | 4.49% | 0.11 |
| SRPTSarepta Therapeutics, Inc. | 2.23B | 21.31 | 9.11 | 52.97% | -11.25% | -20.57% | 0.88 | |
| RAREUltragenyx Pharmaceutical Inc. | 2.27B | 23.50 | -3.74 | 29.01% | -91.95% | -35.88% | 0.15 | |
| DYNDyne Therapeutics, Inc. | 2.7B | 16.42 | -4.87 | -61.26% | 0.04 | |||
| TVTXTravere Therapeutics, Inc. | 2.54B | 28.40 | -6.96 | 60.55% | -20.32% | -120.36% | 6.80 | |
| BEAMBeam Therapeutics Inc. | 3.25B | 32.05 | -7.00 | -83.18% | -7.44% | -42.92% | 0.22 | |
| SLNOSoleno Therapeutics, Inc. | 2.25B | 41.95 | -9.58 | -79.5% | -15.85% | 0.22 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 10.09M | 4.91M |
| Revenue Growth % | - | - | - | - | - | - | -0.51% |
| Cost of Goods Sold | 1K | 12K | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -1K | -12K | 0 | 0 | 0 | 10.09M | 4.91M |
| Gross Margin % | - | - | - | - | - | 1% | 1% |
| Gross Profit Growth % | - | -11% | 1% | - | - | - | -0.51% |
| Operating Expenses | 9.97M | 13.11M | 29.42M | 42.07M | 47.28M | 62.08M | 61.06M |
| OpEx % of Revenue | - | - | - | - | - | 6.15% | 12.43% |
| Selling, General & Admin | 1.57M | 2.29M | 5.56M | 11.37M | 12.09M | 12.65M | 14.64M |
| SG&A % of Revenue | - | - | - | - | - | 1.25% | 2.98% |
| Research & Development | 8.4M | 10.82M | 23.85M | 30.7M | 35.2M | 49.43M | 46.42M |
| R&D % of Revenue | - | - | - | - | - | 4.9% | 9.45% |
| Other Operating Expenses | 0 | 84K | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -9.97M | -13.11M | -29.42M | -42.07M | -47.28M | -51.99M | -56.15M |
| Operating Margin % | - | - | - | - | - | -5.15% | -11.43% |
| Operating Income Growth % | - | -0.31% | -1.24% | -0.43% | -0.12% | -0.1% | -0.08% |
| EBITDA | -9.97M | -13.1M | -29.38M | -42M | -47.21M | -51.92M | -56.1M |
| EBITDA Margin % | - | - | - | - | - | -5.15% | -11.42% |
| EBITDA Growth % | - | -0.31% | -1.24% | -0.43% | -0.12% | -0.1% | -0.08% |
| D&A (Non-Cash Add-back) | 1K | 12K | 36K | 68K | 74K | 70K | 46K |
| EBIT | -9.86M | -13.02M | -29.42M | -41.95M | -45.76M | -47.44M | -52.73M |
| Net Interest Income | 0 | -46K | -200K | -226K | 1.1M | 4.07M | 3.12M |
| Interest Income | 0 | 19K | 123K | 119K | 1.52M | 4.56M | 3.42M |
| Interest Expense | 0 | 65K | 323K | 345K | 420K | 483K | 307K |
| Other Income/Expense | 114K | 19K | -123K | -226K | 1.1M | 4.07M | 3.12M |
| Pretax Income | -9.86M | -13.09M | -29.54M | -42.29M | -46.18M | -47.92M | -53.04M |
| Pretax Margin % | - | - | - | - | - | -4.75% | -10.8% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1.01% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -9.86M | -13.24M | -29.54M | -42.29M | -46.18M | -47.92M | -53.04M |
| Net Margin % | - | - | - | - | - | -4.75% | -10.8% |
| Net Income Growth % | - | -0.34% | -1.23% | -0.43% | -0.09% | -0.04% | -0.11% |
| Net Income (Continuing) | -9.86M | -13.09M | -29.54M | -42.29M | -46.18M | -47.92M | -53.04M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -483.75 | -22.50 | -48.75 | -68.25 | -72.00 | -93.00 | -96.75 |
| EPS Growth % | - | 0.95% | -1.17% | -0.4% | -0.05% | -0.29% | -0.04% |
| EPS (Basic) | -483.75 | -22.50 | -48.75 | -68.25 | -72.00 | -93.00 | -96.75 |
| Diluted Shares Outstanding | 19.88K | 578.85K | 604.77K | 607.4K | 611.71K | 500.63K | 536.44K |
| Basic Shares Outstanding | 19.88K | 578.85K | 604.77K | 607.4K | 611.71K | 500.63K | 536.44K |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 4.77M | 4.65M | 160.4M | 91.89M | 83.61M | 102.18M | 44.21M |
| Cash & Short-Term Investments | 4.11M | 3.92M | 157.15M | 88.97M | 79.08M | 96.34M | 38.75M |
| Cash Only | 4.11M | 3.92M | 157.15M | 42.75M | 24.49M | 96.34M | 38.75M |
| Short-Term Investments | 0 | 0 | 0 | 46.22M | 54.59M | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 250K | 513K | 276K | 396K | 1.21M | 1.97M | 2.28M |
| Total Non-Current Assets | 2K | 40K | 2.49M | 34.59M | 2.04M | 1.76M | 1M |
| Property, Plant & Equipment | 0 | 0 | 1.87M | 1.48M | 1.4M | 1.18M | 934K |
| Fixed Asset Turnover | - | - | - | - | - | 8.54x | 5.26x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 32.46M | -54.54M | 0 | 0 |
| Other Non-Current Assets | 2K | 40K | 620K | 653K | 55.18M | 582K | 69K |
| Total Assets | 4.78M | 4.69M | 162.88M | 126.49M | 85.65M | 103.95M | 45.21M |
| Asset Turnover | - | - | - | - | - | 0.10x | 0.11x |
| Asset Growth % | - | -0.02% | 33.72% | -0.22% | -0.32% | 0.21% | -0.57% |
| Total Current Liabilities | 2.71M | 4.3M | 9.76M | 8.87M | 12.45M | 24.46M | 15.25M |
| Accounts Payable | 2.3M | 1.88M | 3.63M | 2.82M | 1.43M | 3.33M | 1.29M |
| Days Payables Outstanding | 839.5K | 57.12K | - | - | - | - | - |
| Short-Term Debt | 0 | 1.25M | 2.55M | 0 | 1.62M | 1.62M | 1.62M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 1000K | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 11.25M | 882K |
| Current Ratio | 1.76x | 1.08x | 16.43x | 10.36x | 6.72x | 4.18x | 2.90x |
| Quick Ratio | 1.76x | 1.08x | 16.43x | 10.36x | 6.72x | 4.18x | 2.90x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 19.87M | 31.03M | 3.69M | 6.24M | 4.71M | 2.97M | 1.14M |
| Long-Term Debt | 0 | 3.19M | 1.92M | 4.88M | 3.29M | 1.72M | 124K |
| Capital Lease Obligations | 0 | 0 | 1.65M | 1.29M | 1.26M | 1.02M | 736K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 19.87M | 27.83M | 118K | 73K | 161K | 236K | 282K |
| Total Liabilities | 22.58M | 35.33M | 13.46M | 15.12M | 17.16M | 27.44M | 16.39M |
| Total Debt | 0 | 4.45M | 6.38M | 6.53M | 6.32M | 4.61M | 2.77M |
| Net Debt | -4.11M | 521K | -150.77M | -36.22M | -18.17M | -91.73M | -35.99M |
| Debt / Equity | - | - | 0.04x | 0.06x | 0.09x | 0.06x | 0.10x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | -201.65x | -91.07x | -121.93x | -112.58x | -107.65x | -182.90x |
| Total Equity | -17.8M | -30.64M | 149.43M | 111.37M | 68.49M | 76.51M | 28.82M |
| Equity Growth % | - | -0.72% | 5.88% | -0.25% | -0.39% | 0.12% | -0.62% |
| Book Value per Share | -895.71 | -52.93 | 247.08 | 183.36 | 111.96 | 152.82 | 53.73 |
| Total Shareholders' Equity | -17.8M | -30.64M | 149.43M | 111.37M | 68.49M | 76.51M | 28.82M |
| Common Stock | 1K | 1K | 2K | 3K | 3K | 4K | 4K |
| Retained Earnings | -18.21M | -31.3M | -60.84M | -103.13M | -149.31M | -197.23M | -250.27M |
| Treasury Stock | -411K | 27.15M | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -27.81M | 0 | -184K | -558K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -8.57M | -12.62M | -27.52M | -35.88M | -41.68M | -33.27M | -55.96M |
| Operating CF Margin % | - | - | - | - | - | -3.3% | -11.4% |
| Operating CF Growth % | - | -0.47% | -1.18% | -0.3% | -0.16% | 0.2% | -0.68% |
| Net Income | -9.86M | -13.09M | -29.54M | -42.29M | -46.18M | -47.92M | -53.04M |
| Depreciation & Amortization | 1K | 12K | 36K | 68K | 429K | 70K | 46K |
| Stock-Based Compensation | 101K | 196K | 755K | 3.96M | 0 | 4.62M | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -1.59M | 0 | 66K | 434K | 2.94M | -404K | 5.6M |
| Working Capital Changes | 1.19M | 263K | 1.16M | 1.96M | 1.13M | 10.36M | -8.57M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.7M | -226K | 3.73M | -805K | -1.4M | 1.91M | -2.04M |
| Cash from Investing | 0 | -4K | -74K | -79.17M | 23.69M | 55.78M | 0 |
| Capital Expenditures | 0 | -4K | -74K | -93K | -8K | -7K | 0 |
| CapEx % of Revenue | - | - | - | - | - | 0% | - |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 0 | 12.43M | 181.03M | 643K | -241K | 49.14M | -1.62M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 0 | 0 | 51K | 423K | -40K | -2.85M | -246K |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -8.57M | -12.62M | -27.59M | -35.97M | -41.69M | -33.28M | -55.96M |
| FCF Margin % | - | - | - | - | - | -3.3% | -11.4% |
| FCF Growth % | - | -0.47% | -1.19% | -0.3% | -0.16% | 0.2% | -0.68% |
| FCF per Share | -431.20 | -21.80 | -45.63 | -59.22 | -68.16 | -66.48 | -104.32 |
| FCF Conversion (FCF/Net Income) | 0.87x | 0.95x | 0.93x | 0.85x | 0.90x | 0.69x | 1.06x |
| Interest Paid | 0 | 20K | 0 | 207K | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -49.73% | -32.43% | -51.35% | -66.1% | -100.7% |
| Return on Invested Capital (ROIC) | - | - | - | -85.49% | -56.53% | -222.24% | - |
| Gross Margin | - | - | - | - | - | 100% | 100% |
| Net Margin | - | - | - | - | - | -474.96% | -1079.94% |
| Debt / Equity | - | - | 0.04x | 0.06x | 0.09x | 0.06x | 0.10x |
| Interest Coverage | - | -201.65x | -91.07x | -121.93x | -112.58x | -107.65x | -182.90x |
| FCF Conversion | 0.87x | 0.95x | 0.93x | 0.85x | 0.90x | 0.69x | 1.06x |
| Revenue Growth | - | - | - | - | - | - | -51.32% |
Spruce Biosciences, Inc. (SPRB) reported $0.7M in revenue for fiscal year 2024.
Spruce Biosciences, Inc. (SPRB) saw revenue decline by 51.3% over the past year.
Spruce Biosciences, Inc. (SPRB) reported a net loss of $47.9M for fiscal year 2024.
Spruce Biosciences, Inc. (SPRB) has a return on equity (ROE) of -100.7%. Negative ROE indicates the company is unprofitable.
Spruce Biosciences, Inc. (SPRB) had negative free cash flow of $47.5M in fiscal year 2024, likely due to heavy capital investments.